Baker Avenue Asset Management, LP Arrowhead Pharmaceuticals, Inc. Transaction History

Baker Avenue Asset Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$26.2 - $36.08 $157 - $216	-6 Reduced 3.37%	172 $4,000
Q2 2023 Aug 11, 2023	BUY	$25.16 - $41.38 $150 - $248	6 Added 3.49%	178 $6,000
Q4 2022 Feb 13, 2023	BUY	$28.0 - $40.56 $4,816 - $6,976	172 New	172 $6,000
Q4 2021 Feb 11, 2022	SELL	$58.09 - $82.51 $213,771 - $303,636	-3,680 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$58.38 - $84.96 $748,489 - $1.09 Million	-12,821 Reduced 77.7%	3,680 $229,000
Q2 2021 Aug 16, 2021	BUY	$62.15 - $90.32 $482,097 - $700,612	7,757 Added 88.71%	16,501 $1.37 Million
Q1 2021 May 17, 2021	BUY	$61.35 - $90.47 $536,444 - $791,069	8,744 New	8,744 $579,000

294

90.8M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.08B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Baker Avenue Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Baker Avenue Asset Management, LP with notifications on news.